Marc J. Braunstein, MD, PhD, discusses chimeric antigen receptor T-cell therapies, Bruton’s kinase inhibitors, and brentuximab vedotin that were highlighted at the 2020 Chemotherapy Foundation Symposium.
Marc J. Braunstein, MD, PhD
Advertisement
Articles by Marc J. Braunstein, MD, PhD
Marc J. Braunstein, MD, PhD, discusses the greatest challenge that still exists in the treatment paradigm of multiple myeloma.
Advertisement
Latest Updated Articles
Challenges to Overcome in Treating Multiple MyelomaPublished: December 4th 2019 | Updated:
Therapies Discussed at CFS Show Responses for Hematologic MalignanciesPublished: November 4th 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
